Pediatric Behçet’s disease: Experience of a single tertiary center
Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 ye...
Gespeichert in:
Veröffentlicht in: | Archives of rheumatology 2023-06, Vol.38 (2), p.282-290 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 290 |
---|---|
container_issue | 2 |
container_start_page | 282 |
container_title | Archives of rheumatology |
container_volume | 38 |
creator | Acari, Ceyhun Isguder, Rana Torun, Ruya Makay, Balahan Unsal, Sevket Erbil |
description | Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease. |
doi_str_mv | 10.46497/ArchRheumatol.2023.9651 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10481698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A754111759</galeid><sourcerecordid>A754111759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-eb3afa9f280c1727e1398d228b2a4a914cab8ab7564cb90a70b9323db4fb3afc3</originalsourceid><addsrcrecordid>eNptkdFqFDEUhgdRsLR9h4Dg3axJJpNJvCnbsmqhYBG9DmcyZ3ZSZibbJFPqna_hE_ggvolPYtYW64LkIofk-_9zkr8oCKMrIYVu3qyDHT4NuEyQ_LjilFcrLWv2rDjikqlS1pQ-zzUTqqypkC-L0xhvKKVMNFLS6qjYXGPnIAVnyTkOP39g-vXteySdiwgR35LN_Q6Dw9ki8T0BEt28HZEkDMlB-Eoszrk-KV70MEY8fdyPiy_vNp8vPpRXH99fXqyvSiukTiW2FfSge66oZQ1vkFVadZyrloMAzYSFVkHb1FLYVlNoaKsrXnWt6PdKWx0XZw--u6WdsNs3DzCaXXBTHsZ4cObwZnaD2fo7w6hQTGqVHV49OgR_u2BM5sYvYc5DG664zn_KFXuitjCicXPvs5udXLRm3dSCMdbUOlOr_1B5dTg562fsXT4_ELz-RzAgjGmIflyS83M8BNUDaIOPMWD_94mMmj_Jm4PkzT55s0---g3MFqYt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829497281</pqid></control><display><type>article</type><title>Pediatric Behçet’s disease: Experience of a single tertiary center</title><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Acari, Ceyhun ; Isguder, Rana ; Torun, Ruya ; Makay, Balahan ; Unsal, Sevket Erbil</creator><creatorcontrib>Acari, Ceyhun ; Isguder, Rana ; Torun, Ruya ; Makay, Balahan ; Unsal, Sevket Erbil</creatorcontrib><description>Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease.</description><identifier>ISSN: 2148-5046</identifier><identifier>ISSN: 1309-0291</identifier><identifier>EISSN: 2618-6500</identifier><identifier>EISSN: 1309-0283</identifier><identifier>DOI: 10.46497/ArchRheumatol.2023.9651</identifier><language>eng</language><publisher>Istanbul: Turkish League Against Rheumatism</publisher><subject>Adalimumab ; Age ; Antigens ; Cerebrospinal fluid ; Children ; Diseases ; Erythema ; Females ; Histocompatibility antigens ; HLA histocompatibility antigens ; Laboratories ; Leukocytes ; Lupus ; Males ; Medical research ; Medicine, Experimental ; Mutation ; Nervous system ; Original ; Patients ; Pediatrics ; Skin ; Statistical analysis ; Thrombosis ; Ulcers ; Vein & artery diseases</subject><ispartof>Archives of rheumatology, 2023-06, Vol.38 (2), p.282-290</ispartof><rights>COPYRIGHT 2023 Turkish League Against Rheumatism</rights><rights>Copyright Prof Sebnem Ataman, President Turkish League Against Rheumatism 2023</rights><rights>Copyright © 2023, Turkish League Against Rheumatism 2023 Turkish League Against Rheumatism</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c469t-eb3afa9f280c1727e1398d228b2a4a914cab8ab7564cb90a70b9323db4fb3afc3</cites><orcidid>0000-0002-6070-8196 ; 0000-0002-4044-1471 ; 0000-0002-8800-0800 ; 0000-0002-7175-0015 ; 0000-0001-6193-0402</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481698/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481698/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Acari, Ceyhun</creatorcontrib><creatorcontrib>Isguder, Rana</creatorcontrib><creatorcontrib>Torun, Ruya</creatorcontrib><creatorcontrib>Makay, Balahan</creatorcontrib><creatorcontrib>Unsal, Sevket Erbil</creatorcontrib><title>Pediatric Behçet’s disease: Experience of a single tertiary center</title><title>Archives of rheumatology</title><description>Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease.</description><subject>Adalimumab</subject><subject>Age</subject><subject>Antigens</subject><subject>Cerebrospinal fluid</subject><subject>Children</subject><subject>Diseases</subject><subject>Erythema</subject><subject>Females</subject><subject>Histocompatibility antigens</subject><subject>HLA histocompatibility antigens</subject><subject>Laboratories</subject><subject>Leukocytes</subject><subject>Lupus</subject><subject>Males</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mutation</subject><subject>Nervous system</subject><subject>Original</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Skin</subject><subject>Statistical analysis</subject><subject>Thrombosis</subject><subject>Ulcers</subject><subject>Vein & artery diseases</subject><issn>2148-5046</issn><issn>1309-0291</issn><issn>2618-6500</issn><issn>1309-0283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkdFqFDEUhgdRsLR9h4Dg3axJJpNJvCnbsmqhYBG9DmcyZ3ZSZibbJFPqna_hE_ggvolPYtYW64LkIofk-_9zkr8oCKMrIYVu3qyDHT4NuEyQ_LjilFcrLWv2rDjikqlS1pQ-zzUTqqypkC-L0xhvKKVMNFLS6qjYXGPnIAVnyTkOP39g-vXteySdiwgR35LN_Q6Dw9ki8T0BEt28HZEkDMlB-Eoszrk-KV70MEY8fdyPiy_vNp8vPpRXH99fXqyvSiukTiW2FfSge66oZQ1vkFVadZyrloMAzYSFVkHb1FLYVlNoaKsrXnWt6PdKWx0XZw--u6WdsNs3DzCaXXBTHsZ4cObwZnaD2fo7w6hQTGqVHV49OgR_u2BM5sYvYc5DG664zn_KFXuitjCicXPvs5udXLRm3dSCMdbUOlOr_1B5dTg562fsXT4_ELz-RzAgjGmIflyS83M8BNUDaIOPMWD_94mMmj_Jm4PkzT55s0---g3MFqYt</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Acari, Ceyhun</creator><creator>Isguder, Rana</creator><creator>Torun, Ruya</creator><creator>Makay, Balahan</creator><creator>Unsal, Sevket Erbil</creator><general>Turkish League Against Rheumatism</general><general>Prof Sebnem Ataman, President Turkish League Against Rheumatism</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6070-8196</orcidid><orcidid>https://orcid.org/0000-0002-4044-1471</orcidid><orcidid>https://orcid.org/0000-0002-8800-0800</orcidid><orcidid>https://orcid.org/0000-0002-7175-0015</orcidid><orcidid>https://orcid.org/0000-0001-6193-0402</orcidid></search><sort><creationdate>20230601</creationdate><title>Pediatric Behçet’s disease: Experience of a single tertiary center</title><author>Acari, Ceyhun ; Isguder, Rana ; Torun, Ruya ; Makay, Balahan ; Unsal, Sevket Erbil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-eb3afa9f280c1727e1398d228b2a4a914cab8ab7564cb90a70b9323db4fb3afc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adalimumab</topic><topic>Age</topic><topic>Antigens</topic><topic>Cerebrospinal fluid</topic><topic>Children</topic><topic>Diseases</topic><topic>Erythema</topic><topic>Females</topic><topic>Histocompatibility antigens</topic><topic>HLA histocompatibility antigens</topic><topic>Laboratories</topic><topic>Leukocytes</topic><topic>Lupus</topic><topic>Males</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mutation</topic><topic>Nervous system</topic><topic>Original</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Skin</topic><topic>Statistical analysis</topic><topic>Thrombosis</topic><topic>Ulcers</topic><topic>Vein & artery diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Acari, Ceyhun</creatorcontrib><creatorcontrib>Isguder, Rana</creatorcontrib><creatorcontrib>Torun, Ruya</creatorcontrib><creatorcontrib>Makay, Balahan</creatorcontrib><creatorcontrib>Unsal, Sevket Erbil</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Acari, Ceyhun</au><au>Isguder, Rana</au><au>Torun, Ruya</au><au>Makay, Balahan</au><au>Unsal, Sevket Erbil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pediatric Behçet’s disease: Experience of a single tertiary center</atitle><jtitle>Archives of rheumatology</jtitle><date>2023-06-01</date><risdate>2023</risdate><volume>38</volume><issue>2</issue><spage>282</spage><epage>290</epage><pages>282-290</pages><issn>2148-5046</issn><issn>1309-0291</issn><eissn>2618-6500</eissn><eissn>1309-0283</eissn><abstract>Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease.</abstract><cop>Istanbul</cop><pub>Turkish League Against Rheumatism</pub><doi>10.46497/ArchRheumatol.2023.9651</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6070-8196</orcidid><orcidid>https://orcid.org/0000-0002-4044-1471</orcidid><orcidid>https://orcid.org/0000-0002-8800-0800</orcidid><orcidid>https://orcid.org/0000-0002-7175-0015</orcidid><orcidid>https://orcid.org/0000-0001-6193-0402</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2148-5046 |
ispartof | Archives of rheumatology, 2023-06, Vol.38 (2), p.282-290 |
issn | 2148-5046 1309-0291 2618-6500 1309-0283 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10481698 |
source | PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library |
subjects | Adalimumab Age Antigens Cerebrospinal fluid Children Diseases Erythema Females Histocompatibility antigens HLA histocompatibility antigens Laboratories Leukocytes Lupus Males Medical research Medicine, Experimental Mutation Nervous system Original Patients Pediatrics Skin Statistical analysis Thrombosis Ulcers Vein & artery diseases |
title | Pediatric Behçet’s disease: Experience of a single tertiary center |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T20%3A24%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pediatric%20Beh%C3%A7et%E2%80%99s%20disease:%20Experience%20of%20a%20single%20tertiary%20center&rft.jtitle=Archives%20of%20rheumatology&rft.au=Acari,%20Ceyhun&rft.date=2023-06-01&rft.volume=38&rft.issue=2&rft.spage=282&rft.epage=290&rft.pages=282-290&rft.issn=2148-5046&rft.eissn=2618-6500&rft_id=info:doi/10.46497/ArchRheumatol.2023.9651&rft_dat=%3Cgale_pubme%3EA754111759%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829497281&rft_id=info:pmid/&rft_galeid=A754111759&rfr_iscdi=true |